| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 653 | 2017 |
| FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal … J Souglakos, N Androulakis, K Syrigos, A Polyzos, N Ziras, ... British journal of cancer 94 (6), 798-805, 2006 | 521 | 2006 |
| Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients G Kallergi, MA Papadaki, E Politaki, D Mavroudis, V Georgoulias, ... Breast Cancer Research 13, 1-11, 2011 | 449 | 2011 |
| Molecular detection of cytokeratin-19–positive cells in the peripheral blood of patients with operable breast cancer: Evaluation of their prognostic significance A Stathopoulou, I Vlachonikolis, D Mavroudis, M Perraki, C Kouroussis, ... Journal of Clinical Oncology 20 (16), 3404-3412, 2002 | 428 | 2002 |
| Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer PA Theodoropoulos, H Polioudaki, S Agelaki, G Kallergi, Z Saridaki, ... Cancer letters 288 (1), 99-106, 2010 | 366 | 2010 |
| Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients N Xenidis, M Perraki, M Kafousi, S Apostolaki, I Bolonaki, A Stathopoulou, ... Journal of Clinical Oncology 24 (23), 3756-3762, 2006 | 342 | 2006 |
| Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer … R Gray, R Bradley, J Braybrooke, Z Liu, R Peto, L Davies, D Dodwell, ... The lancet 393 (10179), 1440-1452, 2019 | 330 | 2019 |
| Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study N Harbeck, P Rastogi, M Martin, SM Tolaney, ZM Shao, PA Fasching, ... Annals of Oncology 32 (12), 1571-1581, 2021 | 317 | 2021 |
| Different prognostic value of cytokeratin-19 mRNA–positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer M Ignatiadis, N Xenidis, M Perraki, S Apostolaki, E Politaki, M Kafousi, ... Journal of clinical oncology 25 (33), 5194-5202, 2007 | 305 | 2007 |
| Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer N Xenidis, M Ignatiadis, S Apostolaki, M Perraki, K Kalbakis, S Agelaki, ... Journal of Clinical Oncology 27 (13), 2177-2184, 2009 | 300 | 2009 |
| Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early … M Ignatiadis, G Kallergi, M Ntoulia, M Perraki, S Apostolaki, M Kafousi, ... Clinical Cancer Research 14 (9), 2593-2600, 2008 | 293 | 2008 |
| Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC A Kalikaki, A Koutsopoulos, M Trypaki, J Souglakos, E Stathopoulos, ... British journal of cancer 99 (6), 923-929, 2008 | 242 | 2008 |
| DNA repair gene polymorphisms predict favorable clinical outcome in advanced non–small-cell lung cancer A Kalikaki, M Kanaki, H Vassalou, J Souglakos, A Voutsina, ... Clinical lung cancer 10 (2), 118-123, 2009 | 206 | 2009 |
| Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the lightcycler system A Stathopoulou, A Gizi, M Perraki, S Apostolaki, N Malamos, D Mavroudis, ... Clinical Cancer Research 9 (14), 5145-5151, 2003 | 201 | 2003 |
| Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients I Boukovinas, C Papadaki, P Mendez, M Taron, D Mavroudis, ... PloS one 3 (11), e3695, 2008 | 188 | 2008 |
| Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the … D Mavroudis, E Saloustros, N Malamos, S Kakolyris, I Boukovinas, ... Annals of Oncology 26 (7), 1333-1340, 2015 | 181 | 2015 |
| Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells … V Georgoulias, V Bozionelou, S Agelaki, M Perraki, S Apostolaki, ... Annals of oncology 23 (7), 1744-1750, 2012 | 174 | 2012 |
| Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients Z Saridaki, M Tzardi, C Papadaki, M Sfakianaki, F Pega, A Kalikaki, ... PloS one 6 (1), e15980, 2011 | 174 | 2011 |
| Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients G Kallergi, S Agelaki, A Kalykaki, C Stournaras, D Mavroudis, ... Breast cancer research 10, 1-11, 2008 | 168 | 2008 |
| A multicenter randomized clinical trial comparing paclitaxel–cisplatin–etoposide versus cisplatin–etoposide as first-line treatment in patients with small-cell lung cancer D Mavroudis, E Papadakis, M Veslemes, X Tsiafaki, J Stavrakakis, ... Annals of Oncology 12 (4), 463-470, 2001 | 165 | 2001 |
